文献速递耳科与耳神经

单侧聋人工耳蜗植入后的噪声下言语感知:一项随机临床试验

Speech Perception in Noise After Cochlear Implantation for Single-Sided Deafness: A Randomized Clinical Trial.
PubMed 文献 · JAMA Otolaryngol Head Neck Surg · 2025-01-01

这项单中心随机临床试验纳入120例单侧聋成人,随机分入人工耳蜗组、先骨导装置后信号对传助听器组或相反顺序组,试验期后患者选择骨导装置、信号对传助听器或不治疗。随访24个月时,人工耳蜗组噪声下言语感知及疾病特异性生活质量优于骨导装置组、信号对传助听器组和不治疗组。

要点

  • 单侧聋成人随机分入人工耳蜗、骨导装置与信号对传助听器交叉试验或不治疗。
  • 24个月时人工耳蜗组噪声下言语感知优于骨导装置组、信号对传助听器组和不治疗组。
  • 人工耳蜗组自报言语感知能力优于骨导装置组、信号对传助听器组和不治疗组。

核心结论

  • 在单侧聋患者中,随访24个月后人工耳蜗组在噪声下言语感知和疾病特异性生活质量方面优于骨导装置组、信号对传助听器组和不治疗组,患者可部分重获双耳听觉优势。

研究设计与样本

  • 单中心随机临床试验,纳入120例单侧聋成人,女性60例(50.0%),入组时平均(SD)年龄53.0(12.1)岁。
  • 患者随机分入3组:人工耳蜗组;先试用头带式骨导装置再试用信号对传助听器组;先试用信号对传助听器再试用头带式骨导装置组。
  • 试验期后患者选择骨导装置、信号对传助听器或不治疗;随访开始时人工耳蜗28例、骨导装置25例、信号对传助听器34例、不治疗26例。
  • 基线及随访3、6、12、24个月完成测量;数据收集于2014年7月至2021年10月,分析于2022年12月至2023年5月。

主要发现

  • 24个月时人工耳蜗组噪声下言语感知评分显著优于骨导装置组:言语接收阈值差SbeNpe为-4.7 dB(95%CI -6.6至-3.0),SpeNbe为-2.2 dB(95%CI -4.6至-1.1)。
  • 24个月时人工耳蜗组显著优于信号对传助听器组:S0N0差-1.3 dB(95%CI -1.7至-0.2),SbeNpe差-5.3 dB(95%CI -6.0至-3.1)。
  • 24个月时人工耳蜗组显著优于不治疗组:SpeNbe差-6.3 dB(95%CI -7.5至-4.9)。
  • 与不治疗组相比,骨导装置组和信号对传助听器组SpeNbe差分别为-4.1 dB(95%CI -5.2至-1.5)和-4.1 dB(95%CI -6.1至-3.3),SbeNpe差分别为4.0 dB(95%CI 2.6至6.2)和4.6 dB(95%CI 2.8至5.7)。
  • 人工耳蜗组自报言语感知能力显著优于骨导装置组、信号对传助听器组和不治疗组。

临床怎么用

  • 原文结论指出单侧聋患者治疗后可在一定程度上重获双耳听觉的部分优势。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: There is a lack of high level of evidence studies comparing the effect of different treatment options for single-sided deafness (SSD). OBJECTIVE: To determine the effect of a cochlear implant (CI), bone conduction device (BCD), contralateral routing of signals hearing aid (CROS), and no treatment on speech perception in noise outcomes in patients with SSD. DESIGN, SETTING, AND PARTICIPANTS: In this single-center randomized clinical trial, adult patients with SSD were randomized into 3 groups: CI; a trial period with first a BCD on a headband and then a CROS; or a trial period with first a CROS and then a BCD on a headband. After the trial periods, patients opted for a BCD, CROS, or no treatment. Measurements were completed at baseline and at 3, 6, 12, and 24 months of follow-up. Data were collected from July 2014 to October 2021, and data were analyzed from December 2022 to May 2023. INTERVENTIONS: CI, BCD then CROS, or CROS then BCD. MAIN OUTCOMES AND MEASURES: The primary outcome was the speech reception threshold in noise (SRTn), measured with speech and noise from the front (S0N0), speech directed to the poor ear and noise to the better ear (SpeNbe), and vice versa (SbeNpe). The secondary outcome was disease-specific quality of life (QOL). RESULTS: Of 120 included patients, 60 (50.0%) were female, and the mean (SD) age at inclusion was 53.0 (12.1) years. At the start of follow-up, 28 patients received a CI, 25 a BCD, 34 a CROS, and 26 chose no treatment. At 24 months, the CI group had significantly better speech perception in noise scores than the BCD group (difference in SRTn: SbeNpe, -4.7 dB; 95% confidence interval, -6.6 to -3.0; SpeNbe, -2.2 dB; 95% confidence interval, -4.6 to -1.1), the CROS group (difference in SRTn: S0N0, -1.3 dB; 95% confidence interval, -1.7 to -0.2; SbeNpe, -5.3 dB; 95% confidence interval, -6.0 to -3.1), and the no treatment group (difference in SRTn: SpeNbe, -6.3 dB; 95% confidence interval, -7.5 to -4.9). Compared with the no treatment group, the BCD and CROS groups showed significantly better (difference in SRTn for SpeNbe, -4.1 dB [95% confidence interval, -5.2 to -1.5] and -4.1 dB [95% confidence interval, -6.1 to -3.3], respectively) or worse (difference for SbeNpe, 4.0 dB [95% confidence interval, 2.6 to 6.2] and 4.6 dB [95% confidence interval, 2.8 to 5.7], respectively) speech perception in noise. Self-reported speech perception abilities were significantly better for the CI group compared with the BCD, CROS, and no treatment groups. CONCLUSIONS AND RELEVANCE: In this randomized clinical trial, the CI group outperformed the BCD, CROS, and no treatment groups in terms of speech perception in noise and disease-specific QOL in patients with SSD after 24 months of follow-up. These results indicate that patients with SSD can partially regain the advantages of binaural hearing after treatment. TRIAL REGISTRATION: trialregister.nl Identifier: NL4457.

来源:JAMA Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. van Heteren JAA, Wendrich AW, Peters JPM, et al. Speech Perception in Noise After Cochlear Implantation for Single-Sided Deafness: A Randomized Clinical Trial. JAMA Otolaryngol Head Neck Surg. 2025. PMID: 39820302. doi:10.1001/jamaoto.2024.4760

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。